Curative Parathyroidectomy in Primary Hyperparathyroidism Improves Both Systolic and Diastolic Cardiac Dysfunction: A

Ajaz Qadir1, Sameer Purra2, Raiz Ahmad Misgar1

  • 1Department of Endocrinology, Sher-i-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, India.

Clinical Endocrinology
|January 29, 2025
PubMed

Insights

Parathyroidectomy (PTX) significantly improves cardiovascular function in patients with primary hyperparathyroidism (PHPT). This includes enhanced systolic function, as measured by global longitudinal strain (GLS), benefiting overall heart health.

Area of Science:

  • Cardiology
  • Endocrinology
  • Echocardiography

Background:

  • Primary hyperparathyroidism (PHPT) is linked to cardiovascular issues like hypertension and left ventricular hypertrophy, increasing mortality.
  • While diastolic dysfunction in PHPT is known, data on systolic dysfunction and its recovery post-parathyroidectomy (PTX) is limited.

Purpose of the Study:

  • To assess the impact of PTX on cardiovascular parameters in PHPT patients.
  • Specifically evaluate the improvement in systolic dysfunction using conventional and speckle-tracking echocardiography (STE).

Main Methods:

  • Prospective study of 59 PHPT patients undergoing successful PTX.
  • Preoperative and 6-month postoperative evaluations included biochemical tests and echocardiography.
  • Global longitudinal strain (GLS) assessed via STE to evaluate systolic function.

Main Results:

  • Curative PTX normalized serum calcium and phosphorus, reducing PTH and other markers.
  • Significant improvements observed in diastolic parameters (E velocity, E/A ratio).
  • Systolic function improved, with reduced LV mass, improved EF, and enhanced GLS post-PTX. GLS proved more sensitive than EF for detecting systolic improvement.

Conclusions:

  • Parathyroidectomy significantly improves both diastolic and systolic cardiac functions in PHPT patients.
  • The findings support PTX as beneficial for cardiovascular health in PHPT.
  • STE, particularly GLS, is valuable for assessing systolic function changes after PTX.
Abstract

Related Concept Videos

Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...